David Schenkein is pass­ing the reins at Agios to Jack­ie Fouse af­ter a star-mak­ing 10-year run

David Schenkein’s long run as Agios CEO — grow­ing the com­pa­ny from his leg­endary blank sheet of pa­per to a high pro­file pub­lic biotech with close to 500 staffers, two ap­proved drugs on the mar­ket and more ad­vanc­ing in the pipeline — is com­ing to an end.

In 5 months Schenkein is pass­ing the reins of the Cam­bridge, MA-based com­pa­ny to Jack­ie Fouse, the ex-Cel­gene ex­ec who went on to run one of Vivek Ra­maswamy’s biotechs for a short stint. Af­ter Fouse jumped on the Agios board late last year, he says, the reg­u­lar dis­cus­sions with the board about a tran­si­tion plan be­gan to gel. And “it be­came clear that Jack­ie had an in­ter­est in that role.”

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.